InnoCare gets China NMPA approval for Minjuvi in combo with lenalidomide to treat relapsed or refractory diffuse large B─...
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the China National Medical Products Administration (NMPA) has granted approval for Minjuvi (tafasitamab), a humanized Fc- …